Blueprint Medicines Corporation

NasdaqGS:BPMC Rapport sur les actions

Capitalisation boursière : US$6.1b

Blueprint Medicines Croissance future

Future contrôle des critères 6/6

Blueprint Medicines devrait augmenter ses bénéfices et son chiffre d'affaires de 68.6% et de 25.5% par an respectivement. Le BPA devrait croître de de 68.6% par an. Le rendement des capitaux propres devrait être 36.8% dans 3 ans.

Informations clés

68.6%

Taux de croissance des bénéfices

68.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices28.4%
Taux de croissance des recettes25.5%
Rendement futur des capitaux propres36.8%
Couverture par les analystes

Good

Dernière mise à jour18 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Jul 23
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 05
Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Apr 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Apr 05
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Jan 08
Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Dec 18
Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%

Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Nov 20
Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Jul 26
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Apr 16
Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 09
Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value

Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Dec 12
Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt

Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Nov 07
Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Sep 15

Blueprint to seek label expansion for systemic mastocytosis therapy after trial win

Aug 17

Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

Aug 02

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:BPMC - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20269538911223518
12/31/2025714-82-513718
12/31/2024508-74-133-5218
9/30/2024434-128-251-242N/A
6/30/2024363-205-348-333N/A
3/31/2024282-288-430-415N/A
12/31/2023249-507-453-437N/A
9/30/2023216-555-492-479N/A
6/30/2023226-554-515-505N/A
3/31/2023205-581-503-493N/A
12/31/2022204-558-511-502N/A
9/30/2022272-718-404-395N/A
6/30/2022230-702-367-361N/A
3/31/2022221-650-310-306N/A
12/31/2021180-644-302-299N/A
9/30/2021107-411-312-309N/A
6/30/2021828340407409N/A
3/31/2021809325369371N/A
12/31/2020794314384387N/A
9/30/2020811333361367N/A
6/30/202075-395-340-327N/A
3/31/202072-371-321-307N/A
12/31/201967-348-292-278N/A
9/30/201916-362-311-301N/A
6/30/20198-340-291-284N/A
3/31/201944-267-214-206N/A
12/31/201845-237-188-175N/A
9/30/201845-205-165-142N/A
6/30/201852-170N/A-114N/A
3/31/201817-177N/A-138N/A
12/31/201721-148N/A-120N/A
9/30/201727-120N/A-104N/A
6/30/201726-99N/A-96N/A
3/31/201727-85N/A-86N/A
12/31/201628-72N/A-25N/A
9/30/201625-67N/A-19N/A
6/30/201622-63N/A-13N/A
3/31/201618-58N/A-6N/A
12/31/201511-56N/A-32N/A
9/30/20157-57N/A-30N/A
6/30/20153-56N/A-26N/A
3/31/20151-52N/A-24N/A
12/31/2014N/A-46N/A-35N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BPMC devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: BPMC devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: BPMC devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BPMC ( 25.5% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BPMC ( 25.5% par an) devrait croître plus rapidement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de BPMC devrait être élevé dans 3 ans ( 36.8 %)


Découvrir les entreprises en croissance